FindTrial
Sign In

galantamine hydrobromide

DRUG14 trials

Sponsors

Janssen-Cilag S.p.A., Janssen Korea, Ltd., Korea, Janssen Pharmaceutica N.V., Belgium, Johnson & Johnson Pharmaceutical Research & Development, L.L.C., Janssen Cilag Pharmaceutica S.A.C.I., Greece

Conditions

Alzheimer DiseaseAlzheimer's DiseaseBrain DiseasesCognition DisorderDementiaFrontotemporal DementiaMental DisordersNervous System Diseases

Phase 2

A Pilot Study to Explore the Safety and Tolerability of Galantamine HBr in the Treatment of Pick Complex/Frontotemporal Dementia
CompletedNCT00416169
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.Frontotemporal Dementia, Pick Complex
Start: 2003-05-31End: 2004-07-31Updated: 2011-06-08

Phase 3

Treatment of Severe Alzheimer's Disease: Evaluation of Efficacy and Safety of Galantamine Hydrobromide in a Controlled Study
CompletedNCT00216593
Janssen Pharmaceutica N.V., BelgiumAlzheimer Disease, Dementia
Start: 2003-12-31End: 2008-03-31Updated: 2011-06-21
A Study of the Safety and Effectiveness of Galantamine in Patients With Alzheimer's Disease
CompletedNCT00216502
Janssen-Cilag S.p.A.Alzheimer Disease, Brain Diseases, Dementia +1
Start: 2001-08-31End: 2005-11-30Updated: 2011-01-24
A Study to Evaluate the Efficacy and Safety of Galantamine in Patients With Mild Cognitive Impairment
CompletedNCT00236574
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.Alzheimer Disease, Dementia
Start: 2001-05-31End: 2003-11-30Updated: 2011-06-08
A Study to Evaluate the Efficacy and Safety of Galantamine in Patients With Mild Cognitive Impairment
CompletedNCT00236431
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.Alzheimer Disease, Dementia
Start: 2001-05-31End: 2003-12-31Updated: 2011-06-08
A Follow-up Study to Assess Safety and Tolerability of Galantamine Treatment in Individuals With Mild Cognitive Impairment
CompletedNCT00240695
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.Brain Diseases, Cognition Disorder, Mental Disorders +1
Start: 2003-05-31End: 2004-05-31Updated: 2011-05-18
A Study of the Safety and Effectiveness of Two Doses of Galantamine Versus Placebo in the Treatment of Patients With Alzheimer's Disease
CompletedNCT00253188
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.Alzheimer Disease, Dementia
Start: 1997-02-28End: 1998-12-31Updated: 2011-05-18
A Study of the Safety and Effectiveness of Two Doses of Galantamine Versus Placebo in the Treatment of Patients With Alzheimer's Disease
CompletedNCT00253201
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.Alzheimer Disease, Dementia
End: 1997-10-31Updated: 2011-05-18
A Study of the Safety and Effectiveness of a Flexible Dose of Galantamine Versus Placebo in the Treatment of Patients With Alzheimer's Disease
CompletedNCT00253227
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.Alzheimer Disease, Dementia
Start: 1997-07-31End: 1998-12-31Updated: 2011-05-18
Placebo-Controlled Evaluation of Galantamine in the Treatment of Alzheimer's Disease: Safety and Efficacy of a Controlled-Release Formulation
CompletedNCT00253214
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.Alzheimer Disease, Dementia
Start: 2001-03-31End: 2002-07-31Updated: 2011-05-23
A Study of the Safety and Effectiveness of Galantamine Versus Placebo in the Treatment of Patients With Vascular Dementia or Mixed Dementia
CompletedNCT00261573
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.Alzheimer Disease, Vascular Dementia
Start: 1998-12-31End: 2000-12-31Updated: 2011-05-18
Safety and Efficacy of High Dose, Rapid Titration Galantamine in Patients With Alzheimer's Disease
CompletedNCT00338117
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.Alzheimer's Disease, Dementia
Start: 1995-08-31End: 1997-05-31Updated: 2010-04-28

Phase 4

The Efficacy of Galantamine on the Attention and the Frontal Function of the Patients With Dementia of Alzheimer Type
CompletedNCT00216515
Janssen Korea, Ltd., KoreaAlzheimer Disease
Start: 2004-03-31End: 2005-11-30Updated: 2011-01-24

Unknown Phase

A Study of the Safety and Effectiveness of Galantamine Hydrobromide in Patients With Alzheimer's Disease
CompletedNCT00297362
Janssen Cilag Pharmaceutica S.A.C.I., GreeceAlzheimer Disease
Start: 2004-06-30End: 2005-10-31Updated: 2012-03-26

Related Papers

Accelerating randomized clinical trials in Alzheimer’s Disease using generative machine learning model forecasts of progression
Alzheimer s & Dementia2024-12-01
Safety and efficacy of galantamine (Reminyl) in severe Alzheimer's disease (the SERAD study): a randomised, placebo-controlled, double-blind trial.
2008-11-2983 citations